PubMed · 2022 · 23 citations · 0 references
MedicineRadiologyUrologyDiagnostic ImagingDiagnostic RadiologyGenitourinary OncologyMagnetic Resonance ImagingPositron Emission TomographyProstate CancerProstate ImagingRadical ProstatectomyUrologic Cancer DiagnosisClinically Significant Prostate Cancer DetectionMultiparametric ImagingMultiparametric Magnetic Resonance Imaging (Mri)Multiparametric Prostate Magnetic Resonance ImagingProstate Cancer DiagnosisProstate Cancer HistopathologyProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission Tomography
PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) fails to identify some men with significant prostate cancer. Prostate-specific membrane antigen positron emission tomography/computerized tomography (PSMA PET/CT) is recommended for staging of prostate cancer, but its additional benefit above mpMRI alone in local evaluation for prostate cancer is unclear. The study aim was to evaluate the ability of mpMRI and PSMA PET/CT individually and in combination, to predict tumor location and Gleason score ≥3+4 on robot-assisted laparoscopic radical prostatectomy (RALP) histology. MATERIALS AND METHODS: Ga-PSMA PET/CT were collected on the index lesions to perform analysis on detection rates. RESULTS: Ga-PSMA PET/CT, index Gleason score ≥3+4 cancer at RALP was identified in 92%. Only 10% of patients with Gleason score ≤3+4 on biopsy with an SUVmax <5 were upgraded to ≥4+3 on RALP histology, compared to 90% if the SUVmax was >11. CONCLUSIONS: Ga-PSMA PET/CT to mpMRI can improve the detection of significant prostate cancer and improve the ability to identify men suitable for active surveillance.